drugset
drugset / Trial / NCT05906836

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

NCT05906836 ↗

Phase 1 Completed 28 enrolled Eli Lilly and Company
NaSequentialOpen-labelBasic science

Summary

The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study also evaluated the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

Timeline

Start
2023-07-27
Primary completion
2023-10-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Selpercatinib Small molecule 160 mg Oral

Indications

No indication recorded.